# CircNova

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/circnova

- Industry: Biotechnology
- Headquarters: Detroit, US
- Total disclosed funding: $6.6M
- Latest round: Seed (Feb 25, 2025)
- Investors on record: 6

## About

CircNova, Inc. is a biotechnology firm specializing in the development of therapeutic solutions through its innovative AI NovaEngine™ technology for generating and analyzing circular RNA (circRNA).CircNova, Inc. was founded in 2024 in Cambridge, US, focusing on developing circRNA therapeutics for treating undruggable diseases, such as Triple-negative Breast Cancer. In January 2025, the company raised USD 3.3 mn in Seed funding led by South Loop Ventures, with participation from Michigan Rise and Union Heritage Venture Partners. The firm has completed 1 deal to date, with the latest deal occurring on 2025-01-28. The founder's history is currently unspecified.CircNova, Inc. primarily focuses on the development of therapeutic solutions utilizing its proprietary AI NovaEngine™ technology to generate, analyze, and identify circular RNA (circRNA). The core product offerings center on designing and developing circRNA therapeutics aimed at addressing major unmet clinical needs, particularly in treating undruggable diseases such as Triple-negative Breast Cancer. The technology employs advanced AI-guided RNA folding and structure prediction to facilitate high-throughput RNA synthesis, thereby improving the efficiency of therapeutic candidate development. CircNova targets a diverse client base, including research institutions, pharmaceutical companies, and biotechnology firms, operating in key geographical markets such as North America, Europe, and Asia.CircNova's revenue structure is based on strategic partnerships and collaborations with healthcare organizations, research institutions, and pharmaceutical companies, focusing on B2B transactions. The firm engages in licensing agreements and collaborative research projects where clients access CircNova's AI NovaEngine™ technology for therapeutic development. Revenue is generated through milestone payments, royalties on successful product development, or subscription models for ongoing access to their proprietary technology and expertise. CircNova's flagship offerings include circRNA therapeutics, with pricing structures determined by the scope of collaborative efforts, the complexity of therapeutic development, and the specific needs of their partners.Looking ahead, CircNova, Inc. plans to enhance its product offerings and expand into new markets. The company is actively designing new circRNA therapeutics, with anticipated launches in the next 12-18 months. Expansion efforts will focus on penetrating additional markets in Europe and Asia by the end of 2025. The recent Seed funding of USD 3.3 mn will be utilized to support research and development operations, enabling the company to facilitate future staffing initiatives, thereby bolstering its growth strategy.

## Funding rounds

- Seed, Feb 25, 2025, $3.3M — Spark Capital, Invest Detroit, Michigan Rise, Union Heritage Venture Partners, South Loop Ventures, Kalamazoo Forward Ventures
- Seed, Jan 28, 2025, $3.3M — Michigan Rise, Union Heritage Venture Partners, South Loop Ventures

## Investors

- Michigan Rise (https://capitalatlas.ai/funds/michigan-rise) — Seed
- Union Heritage Venture Partners (https://capitalatlas.ai/funds/union-heritage-venture-partners) — Seed
- South Loop Ventures (https://capitalatlas.ai/funds/south-loop-ventures) — Seed
- Spark Capital — Seed
- Invest Detroit (https://capitalatlas.ai/funds/invest-detroit) — Seed
- Kalamazoo Forward Ventures (https://capitalatlas.ai/funds/kalamazoo-forward-ventures) — Seed